Results from the phase II/III PROSPECT trial show that neoadjuvant chemotherapy works just as well as pelvic radiation for patients with locally advanced rectal cancer. Five-year disease-free survival, overall survival, and recurrence rates were almost identical for the two approaches.

You do not currently have access to this content.